Hansoh Pharmaceutical Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Huijuan Zhong
Chief executive officer
CN¥14.8m
Total compensation
| CEO salary percentage | 49.6% |
| CEO tenure | 9yrs |
| CEO ownership | n/a |
| Management average tenure | 8.8yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 41% Above Its Share Price
Dec 10
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly
Nov 21Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?
Nov 04Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥5b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥3b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
Compensation vs Market: Huijuan's total compensation ($USD2.03M) is above average for companies of similar size in the Hong Kong market ($USD881.24K).
Compensation vs Earnings: Huijuan's compensation has increased by more than 20% in the past year.
CEO
Huijuan Zhong (63 yo)
9yrs
Tenure
CN¥14,807,000
Compensation
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 9yrs | CN¥14.81m | no data | |
| Executive Director | 8.8yrs | CN¥9.39m | 0.023% HK$ 24.9m | |
| Executive Director | 9yrs | CN¥16.63m | 0.021% HK$ 22.4m | |
| VP & CFO | no data | no data | no data | |
| Chief of Science Officer | 2.7yrs | no data | no data | |
| Senior Vice President | 15.8yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Joint Company Secretary & Senior VP | 6.3yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
8.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: 3692's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 9yrs | CN¥14.81m | no data | |
| Executive Director | 8.8yrs | CN¥9.39m | 0.023% HK$ 24.9m | |
| Executive Director | 9yrs | CN¥16.63m | 0.021% HK$ 22.4m | |
| Independent Non-Executive Director | 5.6yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.6yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.6yrs | CN¥360.00k | no data |
7.2yrs
Average Tenure
65yo
Average Age
Experienced Board: 3692's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |